Form 4 for BBIO BridgeBio Pharma, Inc.
Accepted 2025-08-22 00:00:00 ET · period of report 2025-08-20 · accession 0000950170-25-110993 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2025-08-22 | 2025-08-20 | BBIO | Kumar Neil | CEO, Dir | S - Sale | $48.82 | -26.2K | 223.5K | -10% | -$1.28M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-20 | S | D | 428 | $49.25 | 223,090 | D | — | — | (F4) Represents the weighted average sale price of the shares sold from $49.22 to $49.26 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2025-08-20 | S | D | 25,728 | $48.81 | 223,518 | D | — | — | (F2) Represents the weighted average sale price of the shares sold from $48.22 to $49.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |